Friday - August 1, 2025
TAGRISSO (osimertinib) Plus Chemotherapy Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in EGFR-Mutated Advanced Lung Cancer
July 22, 2025
WILMINGTON, Delaware, July 22 -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

TAGRISSO (osimertinib) plus chemotherapy demonstrated statistically significant and clinically meaningful improvement in overall survival in EGFR-mutated advanced lung cancer

Longer-term follow up in the FLAURA2 Phase III trial confirms the favorable benefit-risk profile of this combination

Overall survival results reinforce TAGRI . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products